Drug Therapy for Rheumatoid Arthritis in Adults
Comparative Adverse Effects of Oral DMARDs
Oral disease-modifying anti-rheumatic drugs (DMARDs) used as monotherapies exhibit similar adverse event rates. The evidence included 3 randomized controlled trials (RCTs) with a total of 1,839 patients; 1 observational study with a total of 40,594 patients; and 3 meta-analyses with a total of 7,245 patients. The strength of evidence for this finding is moderate.
Adding a corticosteroid to treatment with oral DMARDs does not increase treatment discontinuation rates and may delay discontinuation. The evidence included 4 RCTs with a total of 1,202 patients and 1 observational study with a total of 154 patients. The strength of evidence for this finding is moderate.
Adding a corticosteroid may increase wound healing complications. The strength of evidence for this finding is low.
Oral DMARDs do not appear to elevate the risk of lymphoma. The evidence includes 2 observational studies with a total of 16,545 patients. The strength of evidence for this finding is low.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic DMARD | oral DMARD | nonbiologic DMARD | early RA | methotrexate | sulfasalazine | hydroxychloroquine | disease activity | adverse event | discontinuation | wound healing | lymphoma
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.